Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,209 recruiting studies in this area right now.
By phase
- Not applicable9,535
- Phase 24,407
- Phase 12,674
- Phase 1/Phase 21,653
- Phase 31,394
- Phase 2/Phase 3285
- Phase 4261
Top conditions
- Breast Cancer1,201
- Prostate Cancer645
- Cancer634
- Colorectal Cancer480
- Lung Cancer418
- Ovarian Cancer338
- Multiple Myeloma329
- Pancreatic Cancer290
- Gastric Cancer283
- Acute Myeloid Leukemia280
- Hepatocellular Carcinoma256
- Solid Tumor247
- Advanced Solid Tumor233
- Head and Neck Cancer226
- Cervical Cancer225
- Endometrial Cancer210
- Advanced Solid Tumors203
- Esophageal Cancer190
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University302
- National Cancer Institute (NCI)293
- Memorial Sloan Kettering Cancer Center291
- Sun Yat-sen University274
- Mayo Clinic238
- City of Hope Medical Center145
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences142
- AstraZeneca133
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,414
- Texas635
- Arizona507
- Florida436
- Alabama430
- New York406
- Massachusetts340
- Maryland329
- New Jersey272
- Pennsylvania233
Recruiting studies20,209 total
- NCT07446855RecruitingPhase 1/Phase 2
Study of AZD4956 for advanced solid tumors with DNA repair problems
This trial tests a new drug called AZD4956, alone or with other cancer medicines, for people with advanced solid tumors that have certain DNA repair problems (called homologous recombination deficiency). It may be an option if you have breast, ovarian, prostate, or pancreatic cancer with a specific gene change, and you have or haven't had previous PARP inhibitor treatment.
New York, New YorkAges 18–130 - NCT07450859RecruitingPhase 2
Study of new drug for metastatic pancreatic cancer
This trial tests a new drug called nuzefatide pevedotin for people with metastatic pancreatic cancer that has progressed after one prior treatment. The drug targets a protein called EphA2 found on some tumor cells and may slow tumor growth.
Phoenix, ArizonaAges 18 years+ - NCT07451002Recruiting
Study on Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer
This study looks at how well men with prostate cancer that has spread and is still hormone-sensitive stick to taking the drug apalutamide. It aims to understand real-world use and quality of life.
CaenAges 18 years+ - NCT07444814RecruitingPhase 1
HWK-007 for advanced solid tumors
This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.
Little Rock, ArkansasAges 18 years+ - NCT07452198RecruitingPhase 3
Study of new drug for relapsed or hard-to-treat multiple myeloma
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
TianjinAges 18 years+ - NCT07448922RecruitingPhase 2
Study of SKB518 for advanced gynecologic cancers
This trial tests a new drug called SKB518, either alone or with other treatments, for people with advanced gynecologic cancers (ovarian, cervical, or endometrial) who have already had some treatment. It aims to see if the drug helps shrink or control the cancer.
ChongqingAges 18–75 - NCT07449754RecruitingPhase 2
Belvarafenib with cobimetinib for NRAS-mutant melanoma
This trial tests a combination of two drugs (belvarafenib and cobimetinib) for people with advanced melanoma that has a specific gene change called NRAS. It is for those who have tried other treatments or cannot take them.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07452224RecruitingPhase 2
Combination treatment for advanced lung cancer
This trial tests a new drug, ILKN421H, combined with pembrolizumab (a type of immunotherapy) for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments or has not been treated before. It aims to see if this combination can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07446153RecruitingPhase 1/Phase 2
HRS-8364 for advanced solid tumors
This trial tests a new medicine, HRS-8364, for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if the drug can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18–75 - NCT07446816RecruitingPhase 1
Study of hemay181 for advanced solid tumors
This trial tests a new drug, Hemay181, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it can shrink tumors and how safe it is.
Xinxiang, HenanAges 18–75 - NCT07450599RecruitingPhase 2
Darolutamide plus hormone therapy before prostate cancer surgery
This trial tests a medicine called darolutamide taken with hormone therapy (ADT) before surgery to remove the prostate. It is for men with a high-risk prostate cancer that has not spread to other parts of the body.
Hefei, AnhuiAges 18 years+ - NCT07448116RecruitingPhase 1/Phase 2
Testing MCLA-129 plus ensartinib for advanced solid tumors
This trial tests a new two-drug combination (MCLA-129 and ensartinib) for people with advanced solid tumors that have a specific genetic change called MET amplification or overexpression. The goal is to see if this combo can shrink tumors or stop them from growing when other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07450976RecruitingPhase 2
Targeted drug for advanced biliary tract cancer after standard treatment
This trial tests a new targeted drug (SHR-A1904) in people with advanced biliary tract cancer whose tumors have a specific protein (Claudin18.2) and who have already tried at least one standard treatment. The goal is to see if this drug can shrink the cancer or slow its growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06793553RecruitingPhase 2
Induction chemo then immunotherapy for PD-L1 positive triple negative breast cancer
This trial tests a two-step approach: first a short course of chemotherapy (paclitaxel and bevacizumab), followed by a combination of immunotherapy (atezolizumab) and a different chemotherapy (nab-paclitaxel). It's for people with advanced triple-negative breast cancer that has spread or cannot be removed, and whose tumors have a specific marker called PD-L1. The goal is to see if this sequence works better than standard treatments.
Koto-ku, 3-8-31, TokyoAges 18 years+ - NCT06801340Recruiting
Understanding metabolic risks from adrenal tumors using CT scans
This study looks at CT scans of people with adrenal tumors to understand how the tumor might affect your metabolism. It may help doctors learn more about the condition and improve care.
BolognaAges 18 years+ - NCT05219058Recruiting
Rebuilding after major pelvic cancer surgery
This study looks at reconstruction (how tissue is rebuilt) after very large pelvic cancer surgeries. It may help teams improve the options and support for people having these operations and recovery experiences.
Southampton, HampshireAges 18 years+ - NCT04929899Recruiting
Test of a learning tool during leukemia maintenance
This study checks whether a tablet-based tool (called PeNAT) can be used by children during the usual maintenance treatment phase for ALL (a type of leukemia). It may help families and clinicians better support care at home or during follow-up by testing how well the tool works in real patients.
Los Angeles, CaliforniaAges 4–18 - NCT03740503Recruiting
Study genes in people who respond unusually to treatment
This study looks at stored tumor samples to understand why some people respond much better or much worse than expected. The goal is to learn what the tumor’s genes might be telling doctors about response to treatment.
Toronto, OntarioAges 18 years+ - NCT04962672Recruiting
Tested anesthesia approach for survival in high-grade brain tumors
This study checks whether a specific anesthesia plan used during surgery is practical and safe for people having their first operation for a high-grade brain tumor. If it works well, it may help support better outcomes after surgery.
Toronto, OntarioAges 18 years+ - NCT05412758Recruiting
Breath and blood tests to study stomach and food-pipe cancer
This study looks at how certain “volatile” substances in breath change in people with stomach or food-pipe (oesophageal) cancer, compared with people who have other non-cancer stomach/food-pipe conditions. It may help researchers find better, earlier ways to assess cancer—especially in people who have not started treatment yet.
LondonAges 18–90 - NCT05381103RecruitingPhase 2/Phase 3
PSMA scan to plan prostate surgery and help protect erections
This trial tests whether using a PSMA-PET scan before prostatectomy can guide surgery in a way that helps preserve sexual function. It may be most helpful if you have certain kinds of prostate cancer and want to keep erections after surgery.
Indianapolis, IndianaAges 40–80 - NCT06387342RecruitingPhase 2
Namodenoson for advanced pancreatic cancer
This trial tests an oral drug called Namodenoson for people with advanced pancreatic cancer that has not responded to previous treatments. The goal is to see if the drug can help slow the cancer's growth or improve symptoms.
Petah TikvaAges 18 years+ - NCT06113705Recruiting
Better MRI and blood tests for glioblastoma treatment response
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
RozzanoAges 18 years+ - NCT06436157Recruiting
Genetic testing support through a nurse-led program
This study tests whether a special program led by oncology nurses can help more people with solid tumor cancers get genetic testing. If you are starting a new treatment and have not had genetic testing before, this program may help you learn about your cancer risks and treatment options.
Chico, CaliforniaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,209 recruiting oncology studies from the U.S. registry right now, out of 30,299 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.